FY2024 Earnings Estimate for Danaher Co. (NYSE:DHR) Issued By William Blair

Danaher Co. (NYSE:DHR) – Equities research analysts at William Blair increased their FY2024 earnings per share (EPS) estimates for shares of Danaher in a research note issued to investors on Wednesday, April 24th. William Blair analyst M. Larew now anticipates that the conglomerate will post earnings per share of $7.67 for the year, up from their prior forecast of $7.61. The consensus estimate for Danaher’s current full-year earnings is $7.64 per share.

Several other equities research analysts have also recently weighed in on DHR. Citigroup boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Barclays upped their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday. Bank of America increased their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and upped their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $270.00.

Danaher Stock Up 0.3 %

Danaher stock opened at $246.45 on Friday. The stock’s fifty day moving average is $248.87 and its two-hundred day moving average is $231.08. The stock has a market cap of $182.54 billion, a PE ratio of 41.77, a P/E/G ratio of 4.19 and a beta of 0.83. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the firm earned $2.36 earnings per share. The firm’s quarterly revenue was down 2.6% on a year-over-year basis.

Institutional Investors Weigh In On Danaher

Several hedge funds have recently modified their holdings of DHR. GHP Investment Advisors Inc. boosted its holdings in shares of Danaher by 540.0% during the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock worth $40,000 after purchasing an additional 135 shares during the last quarter. Meridian Wealth Management LLC boosted its stake in Danaher by 99.5% in the 3rd quarter. Meridian Wealth Management LLC now owns 3,264 shares of the conglomerate’s stock worth $810,000 after buying an additional 1,628 shares during the last quarter. Koshinski Asset Management Inc. grew its holdings in Danaher by 16.2% in the 3rd quarter. Koshinski Asset Management Inc. now owns 1,118 shares of the conglomerate’s stock valued at $277,000 after buying an additional 156 shares during the period. Asset Management One Co. Ltd. increased its stake in shares of Danaher by 0.3% during the 3rd quarter. Asset Management One Co. Ltd. now owns 324,221 shares of the conglomerate’s stock valued at $80,439,000 after acquiring an additional 1,051 shares during the last quarter. Finally, Ballast Advisors LLC purchased a new position in shares of Danaher during the 3rd quarter worth about $485,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other Danaher news, EVP Joakim Weidemanis sold 22,433 shares of the firm’s stock in a transaction dated Thursday, April 25th. The shares were sold at an average price of $250.46, for a total transaction of $5,618,569.18. Following the completion of the transaction, the executive vice president now directly owns 90,412 shares in the company, valued at approximately $22,644,589.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joakim Weidemanis sold 22,433 shares of Danaher stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $250.46, for a total value of $5,618,569.18. Following the sale, the executive vice president now owns 90,412 shares of the company’s stock, valued at approximately $22,644,589.52. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 106,565 shares of company stock valued at $26,641,364. Insiders own 11.10% of the company’s stock.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.